Clinical Scorecard: Low DLCO/SB Linked to Faster SSc Progression
At a Glance
| Category | Detail |
|---|---|
| Condition | Systemic Sclerosis (SSc) |
| Key Mechanisms | Baseline DLCO/SB levels and SSc-specific antibodies |
| Target Population | Patients with very early systemic sclerosis |
| Care Setting | Single-center, longitudinal study |
Key Highlights
- Lower DLCO/SB (<70%) associated with higher progression rates to definite SSc (33% vs 8%)
- Progression occurred sooner in patients with lower DLCO/SB (7.7 years vs 10.2 years)
- All progressed patients were positive for SSc-specific antibodies
- Pulmonary function declined over time in patients who did not transition to definite SSc
- Baseline DLCO/SB <70% may serve as a marker for disease progression
Guideline-Based Recommendations
Diagnosis
- Use 2013 ACR/EULAR criteria for defining progression to definite SSc
Management
- Monitor DLCO/SB and SSc-specific antibodies in early SSc patients
Monitoring & Follow-up
- Annual pulmonary function testing recommended for early detection of decline
Risks
- Subclinical disease may be missed without high-resolution computed tomography
Patient & Prescribing Data
Cohort of 73 patients with very early SSc
Subtle pulmonary function decline may occur even in patients not meeting classification criteria
Clinical Best Practices
- Consider DLCO/SB as a potential marker for disease progression
- Evaluate SSc-specific antibodies regularly
- Assess lung function annually in early SSc patients
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
